Spots Global Cancer Trial Database for Interleukin-2 in Metastatic Kidney Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Interleukin-2 in Metastatic Kidney Cancer
Official Title: Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
Study ID: NCT01702909
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.
Detailed Description: In this phase II study, the IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a cohort of kidney cancer patients to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (\> 1440 million IU/m2/year).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Western Regional Medical Center, Inc, Goodyear, Arizona, United States
Contact Details
Name: Walter Quan, MD
Affiliation: Western Regional Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
